Kuoran Medical Laboratory was established on December 11, 2018, and is located at Room 1-102, Building B07, Yongjia Science and Technology Park, Shidai Avenue, Quanshan District, Xuzhou City. The laboratory is a third-party independent medical laboratory. Its legal representative is Bu Lingbin, and it is a wholly-owned subsidiary of Kuoran Biopharmaceutical Technology (Shanghai) Co., Ltd.
The company focuses on tumor genetic testing as its core business and is engaged in non-invasive personalized precision diagnosis and treatment of tumors and companion diagnostics. Its talent team covers clinical medicine, medical laboratory science, pathology, and molecular biology, and it possesses a variety of high-end precision testing instruments suitable for its testing business. The company integrates research and development with testing and is committed to providing safe, precise, and comprehensive personalized health guidance through technological innovation and collaborative sharing.
The laboratory has passed on-site review and acceptance by an expert panel of the Xuzhou Municipal Health Commission and was approved for the Medical Institution Practice License on July 24, 2019. The scope of practice includes the Department of Medical Laboratory Science (including: clinical immunology and serology, and clinical cellular and molecular genetics). In February 2020, the laboratory passed on-site review and acceptance by an expert panel of the Xuzhou Municipal Health Commission, was confirmed to meet the standards for a Level 2 biosafety laboratory, and was approved for the Biosafety Laboratory Filing Certificate.
The laboratory has a total area of 1,409 m2, of which the office area is approximately 500 m2 and the laboratory area is approximately 909 m2. The overall planned area of the laboratory includes a sample receiving and processing room, sample storage room, pathology area, clinical gene amplification testing area, and others.
The total investment in laboratory construction is approximately RMB 15 million, and it is equipped with a variety of high-end precision instruments to meet the needs of clinical medical testing and pathological testing. The clinical gene amplification testing room is currently equipped with real-time fluorescence quantitative PCR instruments, multifunctional nucleic acid detectors, high-speed refrigerated centrifuges, differential pressure control systems, and other auxiliary equipment to meet the needs of clinical gene amplification testing.
The laboratory carries out quality system construction in accordance with the requirements of the ISO15189 quality management system. Through a period of operational verification, a relatively complete quality management system has now basically been established, and it will be further continuously improved and refined during future operations.
The laboratory mainly engages in tumor-related gene testing projects, focusing on precision medication for cancer types such as non-small cell lung cancer and colorectal cancer. In the later stage, it plans to launch gene testing service projects such as KRAS, ALK, ROS1, BRAF, MET, and NRAS after market research and method validation. The laboratory is deeply engaged in the field of molecular pathology testing and will strengthen the construction of pathology laboratories and clinical gene testing laboratories. At the same time, the Xuzhou laboratory also plans to build a CRO R&D center, which will focus on cooperative development with pharmaceutical companies in the Huaihai Economic Zone and carry out scientific research cooperation with customers nationwide.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows